Barbiturates Examples by Duration and Medical Use

Barbiturates are a class of sedative drugs derived from barbituric acid, and while they share a common chemical backbone, individual examples differ dramatically in how fast they act, how long they last, and what they are used for. Phenobarbital, pentobarbital, thiopental, methohexital, butalbital, secobarbital, and amobarbital are among the most widely known, and each occupies a distinct clinical niche. The differences between them come down largely to small changes in their molecular structure, which determine whether a given barbiturate knocks someone out for minutes or sedates them for days.

How Small Structural Differences Create Different Drugs

All barbiturates share a core ring structure called the barbituric acid nucleus. What makes one barbiturate different from another is the set of chemical side chains attached to that ring. Researchers studying 160 different barbiturate variants found that even slight modifications to these side chains could shift a drug from ultra-short-acting to long-acting, changing its behavior in the body entirely.¹ This is why physicians historically had such a wide menu of barbiturates to choose from: swapping a single chemical group could produce a drug suited for a five-minute procedure instead of round-the-clock seizure control.

In practice, barbiturates are grouped by how long their effects last. That classification is the most useful way to understand the major examples, because the duration of action dictates what each drug is actually used for.

Long-Acting Barbiturates

Phenobarbital is the flagship of this category and one of the oldest drugs still in widespread clinical use, having been introduced in 1912. Its effects can persist for well over 24 hours after a single dose, which makes it practical as an around-the-clock seizure medication. Despite over a century of newer drug development, phenobarbital remains the first-line treatment for neonatal seizures according to both the World Health Organization and the International League Against Epilepsy.² Newer alternatives like levetiracetam have been compared head-to-head with phenobarbital, but systematic reviews have not shown them to be clearly more effective at stopping seizures, though they may carry fewer side effects for developing brains.³

Phenobarbital’s long duration is also the source of some of its problems. Because it lingers in the body, it accumulates easily in people with liver or kidney impairment, and drowsiness can be hard to shake. In adults, it has largely been replaced by newer anti-seizure medications that are better tolerated. But in resource-limited settings where drug availability is constrained, phenobarbital remains a workhorse for epilepsy management precisely because it is cheap, stable, and effective.

Barbital (also called barbitone) is another long-acting example, though it has essentially disappeared from clinical practice. It was the very first commercially marketed barbiturate, sold under the trade name Veronal in the early 1900s, and was widely used as a sleeping pill before safer options came along.

Intermediate-Acting Barbiturates

This group includes some of the most recognizable barbiturate names: pentobarbital (Nembutal), secobarbital (Seconal), amobarbital (Amytal), and butalbital. Their effects typically last several hours, shorter than phenobarbital but long enough to serve various medical purposes.

Butalbital is perhaps the most commonly encountered intermediate-acting barbiturate in everyday medicine, because it is an ingredient in widely prescribed headache medications. Compounded with acetaminophen or aspirin and often caffeine, butalbital-containing products have been shown to work in placebo-controlled trials for episodic tension-type headaches.⁴ These combination products remain controversial among headache specialists, however, because frequent use can lead to rebound headaches and physical dependence. Many neurologists prefer to limit prescriptions to occasional use.

Amobarbital has a unique diagnostic role. Under the name sodium amytal, it is the barbiturate injected during the Wada test, a presurgical procedure used before epilepsy surgery to determine which side of the brain controls language and memory.⁵ The drug is injected into one carotid artery at a time, temporarily putting half the brain to sleep while clinicians test the awake half. A study of 88 patients who underwent the Wada test found its results correlated well with direct brain stimulation during surgery, supporting its usefulness as a mapping tool.⁶ Functional MRI has increasingly replaced the Wada test at many centers, but it is still performed when imaging results are ambiguous or unavailable.

Pentobarbital occupies a grimmer place in public awareness. In veterinary medicine, it is the primary euthanasia agent, and in human medicine, it has become associated with end-of-life and assisted-death protocols. At lethal doses of roughly 2 to 10 grams, pentobarbital causes death within 15 to 30 minutes by suppressing breathing and cardiac function.⁷ Its availability in veterinary settings has created a troubling pattern of misuse; case reports describe individuals gaining access to veterinary euthanasia solutions containing pentobarbital for self-harm purposes.

Secobarbital was once one of the most abused barbiturates on the street, sold in distinctive red capsules that earned the nickname “reds” or “red devils.” It is now rarely prescribed, though it still appears in some end-of-life contexts in jurisdictions that permit medically assisted death.

Ultra-Short-Acting Barbiturates

Thiopental and methohexital act within seconds of intravenous injection and wear off within minutes, which makes them useful for brief medical procedures. Thiopental (sold as Pentothal) was for decades the standard induction agent for general anesthesia, putting patients to sleep in the time it takes to count backward from ten. It was also the barbiturate most associated with “truth serum” claims, though the idea that it compels honesty is a myth rooted more in Hollywood than pharmacology.

Methohexital (Brevital) is the ultra-short barbiturate that has best survived the shift to newer anesthetic drugs. It remains the traditional anesthetic of choice for electroconvulsive therapy, where the goal is very brief unconsciousness during a controlled seizure. A recent meta-analysis comparing methohexital to propofol for this purpose found no meaningful difference in how many treatment sessions patients needed or how much their depression improved, suggesting the two drugs are interchangeable for that specific application.⁸ Some clinicians still favor methohexital because it may produce slightly longer therapeutic seizures, though the clinical significance of that difference is debated.

Manufacturing shortages of thiopental in the United States, driven partly by controversy over its use in lethal injection protocols, have effectively pushed propofol into the role that thiopental once held for surgical anesthesia induction. Thiopental is still available and widely used in many other countries.

Barbiturate Coma in Intensive Care

High-dose barbiturate infusion, typically with pentobarbital or thiopental, can induce a medically controlled coma. This is a last-resort treatment for dangerously elevated intracranial pressure, the kind that occurs after severe traumatic brain injury or massive stroke, when the brain is swelling and other therapies have failed. A ten-year review of patients treated with barbiturate coma therapy found it to be a useful method for controlling intracranial pressure that was not responding to standard medical and surgical interventions.⁹

The premise is straightforward: barbiturates reduce the brain’s metabolic demand for oxygen, which decreases blood flow to the brain and lowers pressure inside the skull. But the trade-off is severe. A patient in barbiturate coma needs mechanical ventilation, continuous blood pressure support, and intensive monitoring. The treatment itself carries risks of cardiovascular collapse and infection. It is used only when the alternative, uncontrolled brain swelling, is likely fatal.

Why Most Barbiturates Fell Out of Favor

For roughly the first half of the twentieth century, barbiturates were the default prescription for anxiety, insomnia, and seizures. Their decline was driven by a simple and serious problem: the gap between a therapeutic dose and a lethal dose is dangerously narrow. A historical analysis of the barbiturate era notes that widespread dependence and fatal overdoses, combined with the arrival of newer drug classes in the 1950s and 1960s, brought most barbiturate prescribing to an end except for specific applications like anesthesia induction and certain types of epilepsy.¹⁰

Benzodiazepines, which arrived with chlordiazepoxide (Librium) in 1960 and diazepam (Valium) in 1963, worked on a similar brain system but were far less likely to kill in overdose. They became the replacement for barbiturates in treating anxiety and insomnia almost immediately. Benzodiazepines are not without their own addiction and safety problems, but they offer a substantially wider margin between an effective dose and a fatal one. That single advantage was enough to displace barbiturates from most of their former uses within a generation.

How Barbiturates Interact with Other Drugs

One of the most clinically important properties of barbiturates is their ability to rev up the liver’s drug-processing machinery. Phenobarbital in particular is a potent inducer of liver enzymes, the proteins responsible for breaking down many medications. Research on several barbiturates including phenobarbital, pentobarbital, and others found that the longer a barbiturate lingered in the bloodstream, the more powerfully it stimulated these enzymes. Barbiturates with long half-lives were the most potent enzyme inducers.¹¹

The practical consequence is that taking a barbiturate can make other medications break down faster in your body, reducing their effectiveness. This matters for blood thinners, hormonal birth control, certain antibiotics, and many other drugs. If you are prescribed phenobarbital for seizures, your doctor needs to account for the fact that your body will chew through other co-prescribed medications more quickly than it otherwise would. This enzyme-induction effect is also one reason why barbiturate tolerance develops: the liver gets better and better at clearing the drug, so higher doses become necessary to achieve the same effect.

Dependence and Withdrawal

Physical dependence on barbiturates develops relatively quickly with regular use, and withdrawal can be life-threatening. The withdrawal syndrome resembles alcohol withdrawal, which is not a coincidence since both barbiturates and alcohol enhance the same calming brain signaling system. When that calming influence is suddenly removed, the nervous system rebounds violently. Symptoms can include high blood pressure, rapid heart rate, tremors, fever, seizures, and a delirium marked by hallucinations.¹²

The case report behind that finding is telling: a patient developed barbiturate withdrawal after purchasing butalbital-containing headache medication (Fioricet) online without a prescription. This illustrates how dependence can develop even with a drug many people think of as a simple headache remedy. Because barbiturate withdrawal seizures can be fatal, anyone physically dependent on a barbiturate should taper off under medical supervision rather than stopping abruptly.

Overdose and What Happens in Poisoning

Barbiturate overdose is a medical emergency. The drugs suppress breathing, and that respiratory depression is the primary killer. The state of deep barbiturate poisoning has been compared to profound surgical anesthesia, where the gravest dangers are drug excess and oxygen deprivation.¹³ Patients in severe barbiturate coma may need mechanical ventilation to survive while their body clears the drug.

Treatment depends on which barbiturate was taken. For long-acting barbiturates like phenobarbital, expert recommendations from a toxicology workgroup state that extracorporeal treatment (essentially blood-filtering procedures like hemodialysis) should be considered in severe cases involving prolonged coma, shock, or the need for mechanical ventilation.¹⁴ These filtration methods work better for long-acting barbiturates because phenobarbital is water-soluble enough to be pulled out of the blood effectively. Short-acting barbiturates are more fat-soluble and harder to dialyze, so treatment for those overdoses relies more on supportive care: keeping the airway open, maintaining blood pressure, and waiting for the drug to be metabolized.

Survival after massive barbiturate ingestion is possible with aggressive support. Case reports describe patients recovering from doses that would normally be lethal, including one case of a woman who was found unresponsive with no breathing after ingesting a veterinary euthanasia solution containing pentobarbital. Her coma resolved over 48 hours with intensive care, and she was successfully taken off the ventilator without complications.¹⁵

Barbiturates and Porphyria

One medical situation where barbiturates are firmly off-limits is porphyria, a group of inherited metabolic disorders affecting the production of heme, a component of hemoglobin. All tested barbiturates significantly increased the activity of a key enzyme in the heme-production pathway in animal studies, providing a direct biochemical reason why they can trigger attacks.¹⁶ In people with acute intermittent porphyria, exposure to a barbiturate can provoke a severe attack featuring abdominal pain, neurological dysfunction, and psychiatric symptoms.¹⁷

This is not a minor footnote. Porphyria attacks precipitated by drugs can be medical emergencies. Because barbiturates are among the most reliable triggers, anyone with a known porphyria diagnosis should consider all barbiturates contraindicated, regardless of the specific drug or the intended purpose. This applies equally to phenobarbital prescribed for seizures and to butalbital taken for a headache. Emergency-room physicians and anesthesiologists need to be aware of a porphyria diagnosis before administering any barbiturate, including thiopental for anesthesia induction.

Barbiturates Still in Active Use

Despite being largely displaced, a handful of barbiturates remain in regular clinical use. Phenobarbital continues to be prescribed for epilepsy worldwide, especially in neonates and in low-resource settings. When tested head-to-head against phenytoin (a non-barbiturate anti-seizure drug) for neonatal seizures, the two controlled seizures in fewer than half of patients when used alone, with no significant difference between them.¹⁸ That modest success rate reflects the difficulty of treating neonatal seizures in general, not a failing unique to phenobarbital.

Methohexital holds its niche in electroconvulsive therapy. Butalbital combination products continue to be widely prescribed for headaches, though with increasing caution about overuse. Pentobarbital and thiopental remain available for barbiturate coma in neurointensive care. And amobarbital still serves its diagnostic role in the Wada test at some epilepsy surgery centers. These surviving uses share a common thread: in each case, the specific pharmacological properties of the barbiturate in question offer something that newer drugs do not fully replicate, whether that is phenobarbital’s long track record in neonatal seizures, methohexital’s seizure-lowering threshold in ECT, or amobarbital’s predictable and brief hemispheric suppression in presurgical mapping.